US FDA Grants BRUKINSA^® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.